Bristol-Myers Squibb 2Q Revenues: $4.9 billion (flat) 2Q Earnings: $667 million (-34%) YTD Revenues: $9.5 billion (+1%) YTD Earnings: $1.4 million (-10%) Comments: U.S. pharmaceutical sales increased 5% to $2.2 billion driven by growth of Plavix, Avapro/Avalide, Erbitux, Abilify, Reyataz and Sustiva, and sales of new products Emsam and Orencia. These sales partially offset the loss of exclusivity of Pravachol. R&D expenses increased by 14% to $740 million in the quarter....